Audit: QRS - Ketamine for Health & Longevity

Audit conducted on 12/09/2026 10:18 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every protocol cell, gate item, tier item, monitoring row and qualitative item traces to a specific ER passage (ER lines 363–372, 335–359, 398–414, 461–463, 495–514).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Indefinite ongoing use in healthy people is untested” mirrors ER line 542 “it has simply not been tested”; “How large the effect really is remains unsettled” mirrors ER line 538.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindication thresholds (180/110 mmHg, 6 weeks, Child-Pugh Class C) are carried at ER strength; no avoid-population was demoted to a caution.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from ER “Populations who should avoid Ketamine”; interactions only from the ER interaction bullets; Risk- and Benefit-Modifying Factors are not surfaced anywhere.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, expert names or brand names appear. Every named drug in the gates (diazepam, naltrexone, tranylcypromine, ritonavir, rifampin, etc.) is present in ER lines 335–357.
1.6	The QRS does not introduce new attributions.	🟢	No attribution appears outside the fixed template subline.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The measured, sceptical register of the ER Conclusion is preserved in the lede and throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Tiered benefits and risks, concrete monitoring targets and dosing values, presented without alarm or promotion.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol and cadence are stated descriptively (“Titrated to the longest workable interval”), not as orders.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative or prescriptive constructions anywhere in the sheet.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	All content is declarative or passive-voice reporting of what the ER documents.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns present (verified across the whole file).
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Remaining technical terms (Child-Pugh Class C, CYP3A4, CADSS) are the ER’s own biomarker and gate names, which items 8.4/9.4/14.2 require carrying unexplained.
2.8	Information is presented in a concise and very compact manner	🟢	Every gate item is a bare label plus qualifier; benefit and risk tiers are semicolon-joined headings with magnitudes stripped.
2.9	It DOES NOT address the reader directly	🟢	No direct address anywhere.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Framing assumes a reader weighing a course of treatment, with monitoring targets set at functional rather than conventional thresholds.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Supervised infusion courses, per-session observation and 6-monthly laboratory panels are presented without hedging about burden.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification toward casual readers; the sheet assumes engagement with a clinic-administered protocol.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The lede closes on “Indefinite ongoing use in healthy people is untested”, which is precisely the longevity-audience signal distinct from the treatment-population signal.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur in the document.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Routes are stated formally (“intravenously over 40 minutes”, “Nasal esketamine”, “One infusion weekly”); no consumer-grade substitutes appear.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and column headers match the template byte-for-byte.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Every template variable is present; marker_#* and qualitative_item# are correctly expanded to marker_1..9 and qualitative_item_1..6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural diff against the template shows differences only inside data-qrs-var spans; website=”evidence_review”, website=”audit”, website=”full_review”, the stylesheet link and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section mapped into the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard induction course”, “Maintenance phase”, “Nasal esketamine alternative” and “Duration of benefit” match ER bold labels; the nine marker names match the ER biomarker column verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	time_1_label and time_2_label are lifted from the ER’s own “Time to effect” bullet text (“Mood and suicidal-ideation”, “Pain and post-traumatic stress responses”).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters occur in the file; the ER’s tier and “⚠️ Conflicted” markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed against the ER: 16 protocol bullets to 3 cells, 13 interaction bullets with mitigations to bare labels plus example drugs, benefit and risk entries to headings with magnitudes removed.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype and before the template’s own opening comment.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing “—” at line 13; the descriptive text on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: ketamine_2026-0912-0752_Opus_ER.md, matching the ER’s own filename frontmatter field.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.9.11, matching the version badge of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0912-0948, correctly formatted.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: ketamine_2026-0912-0752_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; quoting used only where YAML requires it.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Ketamine for Health & Longevity - Quick Reference Sheet” (line 22), with the ampersand correctly entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Ketamine for Health & Longevity” (line 417).
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0912-0948 renders as “09/12/2026” (line 421).
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5” (line 425), matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header contains only the title and the fixed template subline; the ER’s “Also known as” list was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses all three Conclusion paragraphs: the rapid effect, the contested magnitude, the use-pattern split in harms, and the untested indefinite use.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Maps to ER lines 538 (rapid effect, unsettled magnitude), 540 (tolerated supervised courses; bladder and bile-duct damage from heavy use) and 542 (untested indefinite use).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “anesthetic”, “bladder”, “bile ducts” are everyday terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial, author, year or sample size is named.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric result appears.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items come from the “Populations who should avoid Ketamine” list at ER lines 363–372.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All ten ER avoid-populations are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Ten <li> elements inside the stop_items span (lines 567–583).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No dash-trailing clauses; the ER’s explanatory glosses (“a tangle of abnormal blood vessels”, “the most advanced grade of liver failure”) were correctly stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	180/110 mmHg threshold, the 6-week infarction window, Child-Pugh Class C, the aneurysm sites and the substance classes are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication list uses no ranking notation.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names ten such populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All thirteen items come from the interaction bullets at ER lines 335–359.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Twelve drug/supplement bullets plus electroconvulsive therapy extracted from the ER “Other interventions” bullet; psychotherapy correctly omitted as the ER states “no restriction”; no overlap with the contraindication gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Thirteen <li> elements inside the caution_items span (lines 589–605).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every item is a class label plus example drugs; the ER’s caution/monitor grades, mechanisms and mitigation sentences are all stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists are retained for every class, trimmed to two or three named agents to fit the one-page budget.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction bullets use no ranking notation.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names thirteen such interactions, and the section is correctly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol section (lines 398–414).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Standard induction course, maintenance phase and the licensed nasal esketamine alternative are the three lead bullets of the ER Protocol section.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Nine of nine populated; “given morning to early afternoon” derives from the ER “Best time of day” bullet within the same section (line 414).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Mood and suicidal ideation, pain and post-traumatic stress, and duration of benefit — the full content of ER lines 461 and 463.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Mood and suicidal ideation (the two leading High-tier benefits) precede pain and post-traumatic stress, with overall duration of benefit last.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects are present in the ER; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Nine of nine populated; “40 minutes to 24 hours”, “4–6 sessions” and “3–7 days per single dose” all match ER lines 461–463.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every listed benefit is an ER Expected Benefits sub-heading.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at the correct tiers.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Six High, two Medium, two Low and two Speculative items, each reduced to the bare ER heading with all Magnitude figures removed.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses occur in any benefits span.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers carry items in the ER, so none needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Every listed risk is an ER Potential Risks & Side Effects sub-heading.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at the correct tiers.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Five High, three Medium, two Low and one Speculative item, each reduced to the bare ER heading with all frequency figures removed.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses occur in any risks span.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers carry items in the ER, so none needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All rows derive from the biomarker table in ER Monitoring Protocol & Defining Success (lines 495–505).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER biomarkers are present with names, targets and rationales matching the ER table.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Baseline within two weeks, per-session 10-minute observations, 24-hour and weekly symptom scores, and the 3-month then 6-monthly repeat schedule, all matching ER lines 491–493.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items derive from the qualitative marker list at ER lines 509–514.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers are present: sleep, energy and motivation, cognitive clarity, interval before symptom return, anhedonia, urinary symptoms.

Issues 12/09/2026 10:18

Pass rate 100.00%. No issues found.

Issues 12/09/2026 10:09

1. 7.4 — Clinical-register word in lede: The At-A-Glance closing sentence “Indefinite maintenance in healthy people is untested” uses “maintenance” in its clinical dosing-phase sense, which a non-specialist would not use unprompted or read as “continued periodic dosing”.

Fixes 12/09/2026 10:09

1. 7.4 — Clinical-register word in lede: Replaced “Indefinite maintenance in healthy people is untested” with “Indefinite ongoing use in healthy people is untested” in [at_a_glance], removing the clinical dosing-phase sense of “maintenance”. The lede remains within the word limit at 57 words.

Issues 12/09/2026 10:00

1. 4.3 — Interaction label paraphrased: The Key Interactions item at line 600, “Blood-pressure-raising supplements (caffeine, yohimbine, synephrine)”, rewords the ER bold label “Supplements with additive blood-pressure effects” (ER line 355) instead of carrying it verbatim.

Fixes 12/09/2026 10:00

1. 4.3 — Interaction label restored verbatim: Replaced the paraphrased Key Interactions item “Blood-pressure-raising supplements (caffeine, yohimbine, synephrine)” with the ER’s own label, “Supplements with additive blood-pressure effects (caffeine, yohimbine, synephrine)”.

Issues 12/09/2026 09:52

1. 4.5 — Sheet exceeds one A4 page: At the template’s print metrics the sheet runs to roughly two A4 pages; the Key Interactions gate alone (lines 594–620) contributes thirteen items carrying full four- and five-drug parentheticals, and the protocol sub-cells (lines 455–487), monitoring cadence (lines 792–798) and qualitative items (lines 806–842) retain ER rationale clauses that item 9.5’s trimming allowance permits condensing.

Fixes 12/09/2026 09:52

1. 4.5 — Key Interactions drug lists trimmed: Shortened every parenthetical example list in the caution gate to two or three representative agents (e.g. the sympathomimetics list from four drugs to “amphetamine, pseudoephedrine”, the sedating-supplement list from five to “valerian, kava, melatonin”), and condensed “Supplements with additive blood-pressure effects” to “Blood-pressure-raising supplements”. No interaction was dropped.
2. 4.5 — Protocol sub-cells condensed: Removed the fasting clause from action_1_sub, which came from the ER’s Risk Mitigation rather than its Protocol section, and tightened action_2_sub and action_3_sub (“Responders titrate to the longest workable interval” to “Titrated to the longest workable interval”).
3. 4.5 — Time-to-effect sub-cells condensed: Shortened time_2_sub to “Responses build over a course, not one dose.” and time_3_sub to “A full course holds for weeks to a couple of months.”
4. 4.5 — Contraindication wording tightened: Trimmed three items while keeping every threshold and time window (“Myocardial infarction within the preceding 6 weeks” to “within 6 weeks”; “Pre-existing ketamine-associated cystitis” to “Ketamine-associated cystitis”).
5. 4.5 — Monitoring cadence condensed: Reduced the cadence sentence from 465 to roughly 385 characters (“every 10 minutes during each session until values return to baseline” to “every 10 minutes per session until baseline returns”).
6. 4.5 — Qualitative rationale clauses trimmed: Stripped the trailing explanatory clauses from all six qualitative items (e.g. “reported immediately rather than at the next scheduled review” to “reported immediately”), leaving the marker itself intact.